Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP7 | P09237 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26787768 | 0.83 | ALDH1A1 (0.64) | LMNAALDH1A1MEN1PKMKMT2A | |
| SCHEMBL5870225 | 0.78 | MMP2 (0.53) | LMNAALDH1A1MEN1PKMKMT2A | |
| SCHEMBL5870228 | 0.78 | MMP2 (0.53) | LMNAALDH1A1MEN1PKMKMT2A | |
| SCHEMBL5870238 | 0.78 | MMP2 (0.53) | LMNAALDH1A1MEN1PKMKMT2A | |
| SCHEMBL20730794 | 0.77 | ALDH1A1 (0.70) | LMNAALDH1A1MEN1PKMKMT2A | |
| SCHEMBL2947860 | 0.76 | LMNA (0.82) | LMNAALDH1A1MEN1PKMKMT2A | |
| SCHEMBL8440592 | 0.76 | ALDH1A1 (0.59) | LMNAALDH1A1MEN1PKMKMT2A | |
| SCHEMBL18639196 | 0.75 | LMNA (0.65) | LMNAALDH1A1MEN1PKMKMT2A | |
| SCHEMBL9872673 | 0.75 | TBXAS1 (0.60) | ALDH1A1MEN1KMT2ACA1CA2 | |
| SCHEMBL14046920 | 0.74 | ALDH1A1 (0.70) | LMNAALDH1A1MEN1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | LMNA 3291/4885ALDH1A1 1681/4885MEN1 4443/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | LMNA 3155/4885ALDH1A1 1490/4885MEN1 4170/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | LMNA 3549/4885ALDH1A1 1415/4885MEN1 4216/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | LMNA 3650/4885ALDH1A1 1184/4885MEN1 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.